GlassScriptPhysician profile
Sanjeev Kamat
NPI 1649375288
$13,913.00
in general payments reported to CMS, 2019-2025
24 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $2,093 · 2021: $2,150 · 2022: $2,163 · 2023: $1,739 · 2024: $2,472 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,501 · Education: $59.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,500.55 |
| Education | $59.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,967.47 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,503.59 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,384.60 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,103.20 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $1,096.36 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,095.45 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $1,066.55 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $968.04 | 2019-2022 | |
| Lundbeck LLC | $694.75 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $459.87 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Indivior INC. | $372.90 | 2019-2023 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $350.72 | 2024-2025 | Cobenfy |
| Allergan, INC. | $324.39 | 2019-2020 | |
| Axsome Therapeutics, INC. | $273.75 | 2022-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $243.43 | 2020-2023 | Belsomra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $238.96 | 2021-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $228.81 | 2022-2024 | Nuplazid |
| Biogen, INC. | $172.53 | 2020-2022 | |
| Livanova USA, INC. | $131.16 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.27 | 2022-2023 | Rexulti, Abilify Asimtufii |
| Lilly USA, LLC | $62.15 | 2025 | Kisunla |
| Bioxcel Therapeutics, INC. | $49.08 | 2023 | Igalmi |
| Noven Therapeutics, LLC | $35.35 | 2021-2022 | |
| Eisai INC. | $24.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.